Weifa ASA: Record-breaking fourth quarter and full year 2016, dividend proposed
February 16, 2017 01:30 ET
|
Weifa ASA
Oslo, 16 February 2017 Record quarterly revenues of NOK 114.5 million, up 17% Driven by Asan and organic growth Fourth quarter adjusted EBITDA of NOK 28.8 million (margin 25.2%) ...
Weifa ASA: Invitation to presentation of Weifa's Q4 2016 results, Thursday 16 February
February 10, 2017 04:00 ET
|
Weifa ASA
Oslo, 10 February 2017 Weifa ASA (OSE: WEIFA), Norway's leading consumer health company, will release its fourth quarter and full-year 2016 results on Thursday 16 February 2017. The results will...
Weifa ASA: New license agreement with AFT Pharmaceuticals for Nordic rights to groundbreaking product line within Pain Management
January 12, 2017 04:15 ET
|
Weifa ASA
Weifa has in-licensed a patented fixed-combination product line within pain management from AFT Pharmaceuticals ("AFT") in New Zealand. The agreement gives rights to commercialize the products in...
Weifa ASA: Launch of the Asan brand in Finland through a cooperation agreement with Midsona Finland Oy.
December 14, 2016 10:01 ET
|
Weifa ASA
Weifa has signed a 3-year cooperation agreement with Midsona Finland Oy(Finland). The agreement covers Weifa's range of Asan products. Midsona will distribute and sell the products on an exclusive...